Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. 2010

Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Activation of autophagy is a hallmark in tumor cells treated with chemotherapy, but the role of autophagy in acquired resistance of lung adenocarcinoma to cisplatin-based chemotherapy remains to be clarified. Our aim was to address that question by surveying the autophagic activity in parental lung adenocarcinoma cell line A549 and its 8-fold, more resistant subcell line, A549/DDP, which was obtained by treating cisplatin with increasing concentrations. A549/DDP and A549 cells were exposed to serum-free culture medium or ionizing radiation. To measure the stress-induced autophagy, LC3-II, as an autophagosome marker, was measured by immunofluorescence and Western blotting. To determine the effect of 3-MA, a known inhibitor of autophagy, on overcoming acquired cisplatin resistance, the MTT assay and flow cytometry were performed. Western blotting analysis demonstrated that LC3-II was increased in A549/DDP cells, compared with those of parental A549 cells, under stress conditions. Meanwhile, immunofluorescence staining showed that LC3-II protein was located mainly in the cytoplasm of A549/DDP. We also found that 3-MA can enhance the growth inhibition and apoptotic effect of cisplatin in acquired resistant cells (A549/DDP). Collectively, our results provide evidence that the upregulation of autophagy plays a major role in cisplatin resistance of A549/DDP cells.

UI MeSH Term Description Entries
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
November 2013, Toxicology mechanisms and methods,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
July 2017, Human cell,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
January 2015, Molecular medicine reports,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
March 1991, The Journal of clinical investigation,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
January 2022, Frontiers in pharmacology,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
April 2018, Japanese journal of clinical oncology,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
May 2012, Molecular and cellular biochemistry,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
February 2020, Anti-cancer drugs,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
June 2022, DNA and cell biology,
Jing-Hua Ren, and Wen-Shan He, and Li Nong, and Qing-Yao Zhu, and Kai Hu, and Rui-Guang Zhang, and Li-Li Huang, and Fang Zhu, and Gang Wu
June 2013, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!